Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Salix Pharmaceuticals has announced that Salix Pharmaceuticals, Norgine, and Norgine Europe, have filed a lawsuit in the US District Court of New Jersey against Novel Laboratories, for infringement of Norgine's patent protecting Moviprep.
Subscribe to our email newsletter
The lawsuit is in response to an abbreviated new drug application filed by Novel with the FDA regarding Novel’s intent to market a generic version of Moviprep in the US prior to the September 1, 2024 expiration of Norgine’s US patent.
Norgine licensed Moviprep to Salix for commercialization in the US. Salix and Norgine have full confidence in the intellectual property rights that protect Moviprep. Moreover, Salix and Norgine intend to use all reasonable means at their disposal to continue to vigorously defend and enforce the intellectual property rights protecting Moviprep.